For example, the administration of tarloxotinib in mice bearing the EGFR-mutant positive NSCLC tumour PC9 is observed to eliminate tumour hypoxia, as detected by pimonidazole (hypoxyprobe) binding three days later (Figure 4). This evidence concerns the gene EGFR and non-small cell lung carcinoma.